Clinical Trials Logo

Recurrent Primary Amyloidosis clinical trials

View clinical trials related to Recurrent Primary Amyloidosis.

Filter by:
  • None
  • Page 1

NCT ID: NCT03499808 Active, not recruiting - Constipation Clinical Trials

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

Start date: June 6, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well isatuximab works in treating patients with primary amyloidosis that has come back or does not respond to treatment. Monoclonal antibodies, such as isatuximab, may interfere with the ability of cancer cells to grow and spread.

NCT ID: NCT03283917 Active, not recruiting - Clinical trials for Recurrent Primary Amyloidosis

Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis

Start date: February 7, 2018
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of daratumumab, ixazomib, and dexamethasone in treating participants with amyloid light chain amyloidosis. Monoclonal antibodies, such as daratumumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as ixazomib and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving daratumumab, ixazomib, and dexamethasone may be effective in treating participants with light chain amyloidosis.

NCT ID: NCT03252600 Active, not recruiting - Clinical trials for Recurrent Primary Amyloidosis

Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis

Start date: August 25, 2017
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well lenalidomide, dexamethasone, and eotuzumab with or without cyclophosphamide work in treating patients with primary amyloidosis that has come back after a period of improvement. Drugs used in chemotherapy, such as lenalidomide, dexamethasone, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as eotuzumab, may interfere with the ability of cancer cells to grow and spread. Giving lenalidomide, dexamethasone, and eotuzumab with cyclophosphamide may work better in treating patients with primary amyloidosis.